Code
NTG-MDSX-02BX
Profile
Active-Compendium
81455
81479
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2-3 mL in EDTA tube. Sodium heparin is acceptable.<br> <b>Peripheral Blood:</b> 3-5 mL in EDTA tube. Sodium heparin is acceptable.<br> <b>H&E slide:</b> Required, plus paraffin block.<br> <b>Cut Slides:</b> H&E slide (required) plus 10-14 unstained slides cut at 5+ microns.<br> <b>Note on FFPE:</b> Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.<br> <b>Do not use:</b> Mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.<br> <b>Note on fresh samples:</b> NeoGenomics should receive within 7 days from collection for acceptable cell viability.<br> <b>Note:</b> Test is TNA-based. Please select Extract & Hold - TNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
<p class="MsoNormal">The Neo Comprehensive - Myeloid Disorders assay analyzes 184 genes to detect DNA and RNA alterations through NGS for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance of myeloid neoplasms. Test reports include a summary interpretation of all results together.</p>
<p class="MsoNormal"><br>DNA sequencing SNVs/Indels (127 genes):<br>ABL1, ANKRD26, APC, ARAF, ASXL1, ATM, ATRX, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CSF3R, CTC1, CUX1, CXCR4, DDX41, DKC1, DNMT3A, ELANE, EPCAM, ERCC4, ETNK1, ETV6, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FLT3, G6PC3, GATA1, GATA2, GFI1, GNAS, GNB1, HAX1, HRAS, IDH1, IDH2, IKZF1, IKZF3, ITPKB, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MAP2K1, MET, MLH1, MPL, MSH2, MSH6, MYD88, NF1, NHP2, NOP10, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIGA, PML, PMS2, PRPF8, PPM1D, PTEN, PTPN11, RAD21, RAD51C, RB1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS26, RPS7, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SLX4, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TERC, TERT, TET2, TINF2, TP53, U2AF1, VHL, WAS, WRAP53, WT1, ZRSR2<br><br>Copy Number Variants (CNV) (17 genes):<br>ABL1, ASXL1, ATG2B, BRAF, CBFB, CDKN1B, CDKN2A, DNMT1, ETV6, EZH2, GSKIP, JAK2, KMT2A, KRAS, MYC, RAD21, TP53<br><br>RNA sequencing Fusions (40 genes):<br>ABL1, AFDN, AFF1, ALK, BCL11B, CBFB, CEP43, CPSF6, CREBBP, DEK, ELL, EP300, ETV6, FGFR1, FLT3, GLIS2, JAK2, KMT2A, MECOM, MLLT1, MLLT3, MRTFA, MYB, MYH11, NTRK3, NUP214, NUP98, PCM1, PDGFRA, PDGFRB, PICALM, PML, PRDM16, RARA, RBM15, RPN1, RUNX1, RUNX1T1, TCF3, ZNF384<br><br>Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.</p>
<p class="MsoNormal"><br>DNA sequencing SNVs/Indels (127 genes):<br>ABL1, ANKRD26, APC, ARAF, ASXL1, ATM, ATRX, BCOR, BCORL1, BLM, BRAF, BRCA1, BRCA2, BRIP1, CALR, CBL, CBLB, CBLC, CDKN2A, CEBPA, CHEK2, CSF3R, CTC1, CUX1, CXCR4, DDX41, DKC1, DNMT3A, ELANE, EPCAM, ERCC4, ETNK1, ETV6, EZH2, FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, FANCM, FBXW7, FLT3, G6PC3, GATA1, GATA2, GFI1, GNAS, GNB1, HAX1, HRAS, IDH1, IDH2, IKZF1, IKZF3, ITPKB, JAK2, JAK3, KDM6A, KIT, KMT2A, KRAS, MAP2K1, MET, MLH1, MPL, MSH2, MSH6, MYD88, NF1, NHP2, NOP10, NOTCH1, NPM1, NRAS, PALB2, PDGFRA, PHF6, PIGA, PML, PMS2, PRPF8, PPM1D, PTEN, PTPN11, RAD21, RAD51C, RB1, RPL11, RPL35A, RPL5, RPS10, RPS17, RPS26, RPS7, RTEL1, RUNX1, SAMD9, SAMD9L, SBDS, SETBP1, SETD2, SF3B1, SH2B3, SLX4, SMC1A, SMC3, SRP72, SRSF2, STAG2, STAT3, STAT5B, SUZ12, TERC, TERT, TET2, TINF2, TP53, U2AF1, VHL, WAS, WRAP53, WT1, ZRSR2<br><br>Copy Number Variants (CNV) (17 genes):<br>ABL1, ASXL1, ATG2B, BRAF, CBFB, CDKN1B, CDKN2A, DNMT1, ETV6, EZH2, GSKIP, JAK2, KMT2A, KRAS, MYC, RAD21, TP53<br><br>RNA sequencing Fusions (40 genes):<br>ABL1, AFDN, AFF1, ALK, BCL11B, CBFB, CEP43, CPSF6, CREBBP, DEK, ELL, EP300, ETV6, FGFR1, FLT3, GLIS2, JAK2, KMT2A, MECOM, MLLT1, MLLT3, MRTFA, MYB, MYH11, NTRK3, NUP214, NUP98, PCM1, PDGFRA, PDGFRB, PICALM, PML, PRDM16, RARA, RBM15, RPN1, RUNX1, RUNX1T1, TCF3, ZNF384<br><br>Note: FLT3 by PCR (via FLT3 Mutation Analysis) is available to be ordered, as Client-Bill only, in conjunction with the Neo Comprehensive Myeloid Disorders. It is reported separately from the Neo Comprehensive profile for the purpose of prompt therapy selection in patients with a new diagnosis of AML.</p>
Orderable Turn Around Time
14 Days
Orderable Biomarkers
NY Approved
True
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["KDM6A", "MAP2K1", "MPL", "PPM1D", "NF1", "RAD21", "RB1", "SETD2", "SMC1A", "SMC3", "STAT3", "STAT5B", "VHL", "SUZ12", "CBLB", "CBLC", "ABL1", "CDKN2A", "ETNK1", "FANCB", "FANCM", "FLT3", "GNB1", "IKZF1", "JAK2", "JAK3", "IKZF3", "ITPKB", "ANKRD26", "PDGFRA", "SH2B3", "TP53", "ASXL1", "BCOR", "BRAF", "CEBPA", "CSF3R", "DNMT3A", "ETV6", "CALR", "EZH2", "IDH1", "KIT", "HRAS", "KRAS", "NPM1", "NRAS", "PHF6", "PTPN11", "PRPF8", "SETBP1", "SF3B1", "SRSF2", "STAG2", "U2AF1", "WT1", "ZRSR2", "BRCA2", "BRIP1", "TET2", "CTC1", "DDX41", "DKC1", "ELANE", "SAMD9L", "RTEL1", "SBDS", "SAMD9", "IDH2", "ERCC4", "G6PC3", "GFI1", "HAX1", "KMT2A", "NHP2", "NOP10", "CUX1", "PALB2", "RAD51C", "RPL11", "RPL35A", "RPL5", "RPS10", "RPS17", "RPS26", "RPS7", "SLX4", "SRP72", "TERC", "PIGA", "TERT", "TINF2", "WRAP53", "PML", "WAS", "ATM", "RUNX1", "BRCA1", "CHEK2", "FANCA", "FANCC", "FANCD2", "FANCE", "FANCF", "FANCI", "FANCL", "FANCG", "MET", "MLH1", "MSH2", "MSH6", "PMS2", "PTEN", "APC", "CXCR4", "MYD88", "NOTCH1", "EPCAM", "FBXW7", "ATRX", "ARAF", "BCORL1", "BLM", "CBL", "GATA1", "GATA2", "GNAS"], "CNVs": ["ABL1", "ASXL1", "CDKN1B", "DNMT1", "CDKN2A", "ETV6", "EZH2", "KMT2A", "MYC", "TP53", "RAD21", "ATG2B", "GSKIP", "JAK2", "KRAS", "BRAF"]}, "RNA Sequencing": {"Fusions": ["PCM1", "PML", "RARA", "RUNX1T1", "ALK", "MYB", "BCL11B", "CBFB", "CEP43", "CPSF6", "MYH11", "DEK", "ABL1", "EP300", "ETV6", "FGFR1", "FLT3", "JAK2", "KMT2A", "AFDN", "AFF1", "NTRK3", "NUP98", "PDGFRA", "PDGFRB", "MECOM", "MRTFA", "RUNX1", "TCF3", "ZNF384", "PICALM", "PRDM16", "RBM15", "RPN1", "CREBBP", "ELL", "GLIS2", "MLLT1", "MLLT3", "NUP214"]}, "Fluorescence In Situ Hybridization (FISH)": {"CNVs": ["CBFB"]}}
Keywords string
Myeloid CGP Comprehensive genomic profiling heme NGS Neo Comprehensive - Myeloid Disorders
Title URL
neo-comprehensive-myeloid-disorders
Clinical Significance
The Neo Comprehensive - Myeloid Disorders assay detects relevant aberrations for the purpose of diagnostic evaluation, prognosis, risk stratification, and therapy guidance. It covers a wide spectrum of myeloid neoplasms, including acute myeloid leukemia (AML); chronic myeloid leukemia (CML); chronic myelomonocytic leukemia (CMML); myelodysplastic neoplasms (MDS); myeloproliferative neoplasms (MPN), e.g., polycythemia vera (PV), primary myelofibrosis (PMF), and essential thrombocythemia (ET); myeloid neoplasms with eosinophilia and defining gene rearrangement; histiocytic neoplasms, such as Langerhans cell histiocytosis (LCH) or Erdheim-Chester Disease (ECD); mastocytosis; myeloid precursor lesions.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible. NYS clients please provide date and time of collection. Please select Extract & Hold - TNA if specimen hold service is desired.